Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Nasus Pharma Ltd. (NSRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
2Distinct source URLs
6High confidence
0.784Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Nasus Pharma Ltd. Suppliers
Ticker
Name
Confidence
Evidence
APTAR
APTAR
92%
as a small pharmaceutical development company, Aptar, a leading global manufacturer of inhalers, is our sole supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery …
Reciprocal relationship from CGEN graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from CGEN g…
Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY g…
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne…
Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI g…
Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY g…
ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER
ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER
62%
cluding use restrictions contained in the product’s approved labeling; ● distribution and use restrictions imposed by the EMA, FDA or other regulatory authority or agreed to by us as part of a mandat…
APTAR-GROUP-INC
APTAR-GROUP-INC
62%
tion of investigations by regulators or other authorities; and ● the inability to successfully commercialize our product candidates, if approved. 24 Further, our business exposes us to an inherent ri…
Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from PLX grap…
Nasus Pharma Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
NSRX-DEBT-17124
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
NSRX-DEBT
Debt stack $118,000
90%
Market cache reports total debt of $118,000.
Nasus Pharma Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nasus Pharma Ltd..
Nasus Pharma Ltd. Ownership
Holder
Name
Confidence
Evidence
NSRX-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 378; value $835; as of 2025-12-31.
NSRX-OWNER-MORGAN-STANLEY
Morgan Stanley
95%
13F/ownership overlay lists Morgan Stanley; shares held 2,000; ownership 0.02%; value $4,420; as of 2025-12-31.
NSRX-OWNER-BALYASNY-ASSET-MANAGEMENT-L-P
Balyasny Asset Management L.P.
90%
13F overlay lists Balyasny Asset Management L.P. as top holder; 9 tracked holders.
